ES2255255T3 - Uso de cabergolina en el tratamiento del sindrome de las piernas inquietas. - Google Patents

Uso de cabergolina en el tratamiento del sindrome de las piernas inquietas.

Info

Publication number: ES2255255T3
Authority: ES; Spain
Prior art keywords: patients; rls; cabergoline; treatment; sleep
Prior art date: 1998-03-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES99914882T

Other languages

English (en)

Spanish (es)

Inventor

Peter Schueler

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pharmacia and Upjohn Co LLC

Original Assignee

Pharmacia and Upjohn Co LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-27

Filing date

1999-03-24

Publication date

2006-06-16

1999-03-24 Application filed by Pharmacia and Upjohn Co LLC filed Critical Pharmacia and Upjohn Co LLC

2006-06-16 Application granted granted Critical

2006-06-16 Publication of ES2255255T3 publication Critical patent/ES2255255T3/es

2019-03-24 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 title claims abstract description 77
229960004596 cabergoline Drugs 0.000 title claims abstract description 77
208000011580 syndromic disease Diseases 0.000 title claims description 8
238000011282 treatment Methods 0.000 title description 73
208000005793 Restless legs syndrome Diseases 0.000 claims abstract description 130
239000003814 drug Substances 0.000 claims abstract description 58
238000004519 manufacturing process Methods 0.000 claims abstract description 5
150000003839 salts Chemical class 0.000 claims abstract description 5
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 63
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 63
229960004502 levodopa Drugs 0.000 claims description 50
229940079593 drug Drugs 0.000 description 53
208000024891 symptom Diseases 0.000 description 52
230000007958 sleep Effects 0.000 description 46
230000000694 effects Effects 0.000 description 33
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 28
YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 17
238000002560 therapeutic procedure Methods 0.000 description 17
239000003136 dopamine receptor stimulating agent Substances 0.000 description 16
229940001089 sinemet Drugs 0.000 description 12
229960004851 pergolide Drugs 0.000 description 11
239000000556 agonist Substances 0.000 description 9
230000007423 decrease Effects 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 8
229960001253 domperidone Drugs 0.000 description 8
229960003638 dopamine Drugs 0.000 description 8
229940005501 dopaminergic agent Drugs 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
230000000737 periodic effect Effects 0.000 description 8
230000035807 sensation Effects 0.000 description 8
230000008901 benefit Effects 0.000 description 7
230000006872 improvement Effects 0.000 description 7
208000035824 paresthesia Diseases 0.000 description 7
238000009097 single-agent therapy Methods 0.000 description 7
229960002802 bromocriptine Drugs 0.000 description 6
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 6
238000000034 method Methods 0.000 description 6
230000004622 sleep time Effects 0.000 description 6
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 5
206010028813 Nausea Diseases 0.000 description 5
206010038743 Restlessness Diseases 0.000 description 5
230000002411 adverse Effects 0.000 description 5
239000001961 anticonvulsive agent Substances 0.000 description 5
229940049706 benzodiazepine Drugs 0.000 description 5
230000002354 daily effect Effects 0.000 description 5
201000010099 disease Diseases 0.000 description 5
229940052760 dopamine agonists Drugs 0.000 description 5
230000008693 nausea Effects 0.000 description 5
229940005483 opioid analgesics Drugs 0.000 description 5
229940088507 permax Drugs 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
208000001431 Psychomotor Agitation Diseases 0.000 description 4
150000001557 benzodiazepines Chemical class 0.000 description 4
DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
208000002173 dizziness Diseases 0.000 description 4
230000009467 reduction Effects 0.000 description 4
208000019116 sleep disease Diseases 0.000 description 4
206010019233 Headaches Diseases 0.000 description 3
208000018737 Parkinson disease Diseases 0.000 description 3
208000012886 Vertigo Diseases 0.000 description 3
206010047700 Vomiting Diseases 0.000 description 3
229940125681 anticonvulsant agent Drugs 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
230000007717 exclusion Effects 0.000 description 3
231100000869 headache Toxicity 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
229940127240 opiate Drugs 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
229940068196 placebo Drugs 0.000 description 3
239000000902 placebo Substances 0.000 description 3
230000004044 response Effects 0.000 description 3
230000004620 sleep latency Effects 0.000 description 3
231100000889 vertigo Toxicity 0.000 description 3
230000008673 vomiting Effects 0.000 description 3
IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 2
101150049660 DRD2 gene Proteins 0.000 description 2
208000001953 Hypotension Diseases 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
206010028735 Nasal congestion Diseases 0.000 description 2
BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
206010041349 Somnolence Diseases 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000009471 action Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229960004205 carbidopa Drugs 0.000 description 2
TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229960003120 clonazepam Drugs 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
239000002804 dopamine agent Substances 0.000 description 2
230000003291 dopaminomimetic effect Effects 0.000 description 2
238000002651 drug therapy Methods 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
229960002870 gabapentin Drugs 0.000 description 2
235000015220 hamburgers Nutrition 0.000 description 2
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
229940073092 klonopin Drugs 0.000 description 2
230000002197 limbic effect Effects 0.000 description 2
238000011866 long-term treatment Methods 0.000 description 2
238000002483 medication Methods 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
229940124641 pain reliever Drugs 0.000 description 2
229940000596 parlodel Drugs 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
229960001879 ropinirole Drugs 0.000 description 2
UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 2
208000020685 sleep-wake disease Diseases 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
230000002618 waking effect Effects 0.000 description 2
DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
206010001540 Akathisia Diseases 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
229940123736 Decarboxylase inhibitor Drugs 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
206010013886 Dysaesthesia Diseases 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
208000004547 Hallucinations Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
208000016285 Movement disease Diseases 0.000 description 1
208000001089 Multiple system atrophy Diseases 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
229940123257 Opioid receptor antagonist Drugs 0.000 description 1
206010031127 Orthostatic hypotension Diseases 0.000 description 1
206010035039 Piloerection Diseases 0.000 description 1
206010062519 Poor quality sleep Diseases 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
208000020764 Sensation disease Diseases 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
VOKSWYLNZZRQPF-UHFFFAOYSA-N Talwin Chemical compound C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-UHFFFAOYSA-N 0.000 description 1
SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000004308 accommodation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229940052036 carbidopa / levodopa Drugs 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
239000003874 central nervous system depressant Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
230000009193 crawling Effects 0.000 description 1
229940078435 darvocet Drugs 0.000 description 1
239000003954 decarboxylase inhibitor Substances 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
229960004193 dextropropoxyphene Drugs 0.000 description 1
XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
QMQBBUPJKANITL-MYXGOWFTSA-N dextropropoxyphene hydrochloride Chemical compound [H+].[Cl-].C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 QMQBBUPJKANITL-MYXGOWFTSA-N 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
230000005284 excitation Effects 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
230000000322 hemodialysis Effects 0.000 description 1
LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
229960000240 hydrocodone Drugs 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
206010021654 increased appetite Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229960004391 lorazepam Drugs 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
229960003987 melatonin Drugs 0.000 description 1
229960001797 methadone Drugs 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
229960004127 naloxone Drugs 0.000 description 1
230000003533 narcotic effect Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
230000000701 neuroleptic effect Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
229960001454 nitrazepam Drugs 0.000 description 1
231100001079 no serious adverse effect Toxicity 0.000 description 1
230000000422 nocturnal effect Effects 0.000 description 1
238000010606 normalization Methods 0.000 description 1
239000003401 opiate antagonist Substances 0.000 description 1
229940052740 other dopaminergic agent in atc Drugs 0.000 description 1
229960002085 oxycodone Drugs 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
229960005301 pentazocine Drugs 0.000 description 1
229940011043 percocet Drugs 0.000 description 1
229960001511 pergolide mesylate Drugs 0.000 description 1
UWCVGPLTGZWHGS-ZORIOUSZSA-N pergolide mesylate Chemical compound CS(O)(=O)=O.C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 UWCVGPLTGZWHGS-ZORIOUSZSA-N 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
238000001907 polarising light microscopy Methods 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
229940035613 prozac Drugs 0.000 description 1
229940001470 psychoactive drug Drugs 0.000 description 1
239000004089 psychotropic agent Substances 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000036280 sedation Effects 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
201000002859 sleep apnea Diseases 0.000 description 1
230000003860 sleep quality Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000010972 statistical evaluation Methods 0.000 description 1
201000009032 substance abuse Diseases 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229940066690 talwin Drugs 0.000 description 1
229960003188 temazepam Drugs 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000008719 thickening Effects 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000036642 wellbeing Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Psychology (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ES99914882T 1998-03-27 1999-03-24 Uso de cabergolina en el tratamiento del sindrome de las piernas inquietas. Expired - Lifetime ES2255255T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7963998P	1998-03-27	1998-03-27
US79639P		1998-03-27

Publications (1)

Publication Number	Publication Date
ES2255255T3 true ES2255255T3 (es)	2006-06-16

Family

ID=22151836

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES99914882T Expired - Lifetime ES2255255T3 (es)	1998-03-27	1999-03-24	Uso de cabergolina en el tratamiento del sindrome de las piernas inquietas.

Country Status (23)

Country	Link
US (1)	US6114326A (de)
EP (1)	EP1066038B1 (de)
JP (1)	JP2002507562A (de)
KR (1)	KR100597517B1 (de)
CN (1)	CN1303286A (de)
AT (1)	ATE313326T1 (de)
AU (1)	AU747751B2 (de)
BR (1)	BR9908953A (de)
CA (1)	CA2320204A1 (de)
CZ (1)	CZ297284B6 (de)
DE (1)	DE69929041T2 (de)
DK (1)	DK1066038T3 (de)
EA (1)	EA002554B1 (de)
ES (1)	ES2255255T3 (de)
HU (1)	HUP0101954A3 (de)
IL (1)	IL138522A0 (de)
NO (1)	NO20004799L (de)
NZ (1)	NZ507176A (de)
PL (1)	PL343593A1 (de)
SK (1)	SK13312000A3 (de)
TR (1)	TR200002759T2 (de)
WO (1)	WO1999048484A2 (de)
ZA (1)	ZA200004452B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6375957B1 (en)	1997-12-22	2002-04-23	Euro-Celtique, S.A.	Opioid agonist/opioid antagonist/acetaminophen combinations
TR200001942T2 (tr)	1997-12-22	2000-11-21	Euro-Celtique, S.A.	Opioid agonist/antagonist kombinasyonlar
US6477408B1 (en) *	2000-03-07	2002-11-05	Northwestern University	Analysis of muscular activity in neonatal animals to screen for mutations and/or drugs that alter sleep and wake states
GB0007308D0 (en)	2000-03-24	2000-05-17	Pharmacia & Upjohn Spa	Process for preparing crystalline form \| of cabergoline
GB0007309D0 (en) *	2000-03-24	2000-05-17	Pharmacia & Upjohn Spa	Crystalline form V\|\| of cabergoline
US6426713B1 (en) *	2000-07-05	2002-07-30	Cirrus Logic, Inc.	Independent control of calibration registers in a multi channel A-D converter
DE10043321B4 (de) *	2000-08-24	2005-07-28	Neurobiotec Gmbh	Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) *	2000-10-20	2002-05-02	Schering Ag	Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
AR031152A1 (es) *	2000-10-31	2003-09-10	Upjohn Co	Tratamientos nuevos para el sindrome de piernas inquietas
DE10064453A1 (de) *	2000-12-16	2002-07-04	Schering Ag	Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20020123503A1 (en) *	2000-12-21	2002-09-05	Malcolm Ross	Cabergoline pharmaceutical compositions and methods of use thereof
JP4453254B2 (ja) *	2001-03-30	2010-04-21	東レ株式会社	レストレス・レッグズ症候群治療薬
EP1387673B1 (de)	2001-05-11	2010-12-29	Endo Pharmaceuticals Inc.	Opioid enthaltende arzneiform gegen missbrauch
US20030134844A1 (en) *	2001-10-31	2003-07-17	Pfizer Inc.	Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
US20030176822A1 (en) *	2002-03-12	2003-09-18	Morgenlander Joel C.	Method of treating restless leg syndrome
LT2425821T (lt)	2002-04-05	2017-07-25	Euro-Celtique S.A.	Farmacinis preparatas, turintis oksikodono ir naloksono
US20040048779A1 (en) *	2002-05-06	2004-03-11	Erwin Schollmayer	Use of rotigotine for treating the restless leg syndrome
ATE400275T1 (de)	2002-08-30	2008-07-15	Kyowa Hakko Kogyo Kk	Adenosin-a2a-rezeptorantagonisten zur behandlung des syndroms der unruhigen beine oder nächtlichen myoklonus
CA2538802C (en)	2003-09-17	2015-01-27	Xenoport, Inc.	Treating or preventing restless legs syndrome using prodrugs of gaba analogs
EP1604666A1 (de)	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
EP1604667A1 (de) *	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioide zur Behandlung des Restless Leg Syndroms
KR20060030175A (ko) *	2004-10-05	2006-04-10	경북대학교 산학협력단	무정위성 운동 치료용 약학조성물
KR100905511B1 (ko) *	2005-01-28	2009-07-01	유로-셀띠끄 소시에떼 아노님	알코올 저항성 제형
EP1702558A1 (de)	2005-02-28	2006-09-20	Euro-Celtique S.A.	Verfahren und Vorrichtung zur Darmtätigkeitserfassung
EP1695700A1 (de) *	2005-02-28	2006-08-30	Euro-Celtique S.A.	Darreichungsform enthaltend Oxycodon und Naloxon
WO2007089335A2 (en) *	2005-12-29	2007-08-09	Lexicon Pharmaceutical Inc.	Multicyclic amino acid derivatives and methods of their use
AU2007235517B2 (en) *	2006-04-03	2013-01-31	Teva Pharmaceutical Industries, Ltd.	Use of rasagiline for the treatment of Restless Legs Syndrome
WO2008046149A1 (en) *	2006-10-17	2008-04-24	Biologic Health Solutions Pty Ltd	Herbal compositions for the prevention or treatment of restless leg syndrome
EP1952813A1 (de) *	2007-02-01	2008-08-06	Ferring International Center S.A.	Medikament zur Behandlung von Endometriose
EP1987815A1 (de) *	2007-05-04	2008-11-05	Schwarz Pharma Ag	Im Mund-Nasen-Rachenraum verabreichbare pharmazeutische Zusammensetzungen enthaltend Dopaminagonisten zur Vorbeugung und/oder Behandlung von unruhigen Gliedmassen
US7939665B2 (en)	2007-05-04	2011-05-10	Apotex Pharmachem Inc.	Efficient process for the preparation of cabergoline and its intermediates
EP2083008A1 (de) *	2007-12-07	2009-07-29	Axxonis Pharma AG	Ergolin-Derivate als selektive Radikalfänger für Neuronen
PL2405915T3 (pl)	2009-03-10	2019-05-31	Euro Celtique Sa	Kompozycje farmaceutyczne o natychmiastowym uwalnianiu zawierające oksykodon i nalokson
CN102448444B (zh)	2009-04-01	2016-05-25	巴尔-波特拉及康邦亚股份有限公司	包括硝基儿茶酚衍生物的药物制剂及其制备方法
US8690933B2 (en) *	2009-08-31	2014-04-08	Brigham Young University	System and method for treating symptoms of restless legs syndrome
US20140045900A1 (en)	2011-02-11	2014-02-13	Bial-Portela & Ca, S.A.	Administration regime for nitrocatechols
KR20160034352A (ko)	2013-07-23	2016-03-29	유로-셀티큐 에스.에이.	장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
PL232974B1 (pl) *	2015-12-09	2019-08-30	Ofta Spolka Z Ograniczona Odpowiedzialnoscia	Zastosowanie agonistów receptorów dopaminergicznych typu 2 w leczeniu schorzeń oczu wywołanych przez podwyższony poziom śródbłonkopochodnego czynnika wzrostu naczyń
WO2021067751A1 (en)	2019-10-03	2021-04-08	Noctrix Health, Inc.	Peripheral nerve stimulation for restless legs syndrome
EP3565631B1 (de)	2017-01-05	2024-04-24	Noctrix Health, Inc.	Behandlung von restless-leg-syndrom oder überaktiven nerven
AU2018258117A1 (en)	2017-04-24	2019-12-12	Chase Therapeutics Corporation	Compositions and method for treating depression
EP4041376A1 (de)	2019-10-03	2022-08-17	Noctrix Health, Inc.	Periphere nervenstimulation für restless-leg-syndrom

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4526892A (en) *	1981-03-03	1985-07-02	Farmitalia Carlo Erba, S.P.A.	Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
US5496836A (en) *	1994-05-05	1996-03-05	Mount Sinai School Of Medicine Of The City University Of New York	Use of famotidine and related compounds in the treatment of movement disorders

1999
- 1999-03-24 PL PL99343593A patent/PL343593A1/xx unknown
- 1999-03-24 HU HU0101954A patent/HUP0101954A3/hu unknown
- 1999-03-24 US US09/275,739 patent/US6114326A/en not_active Expired - Fee Related
- 1999-03-24 TR TR2000/02759T patent/TR200002759T2/xx unknown
- 1999-03-24 CN CN99803305A patent/CN1303286A/zh active Pending
- 1999-03-24 WO PCT/US1999/004269 patent/WO1999048484A2/en not_active Ceased
- 1999-03-24 AU AU33531/99A patent/AU747751B2/en not_active Ceased
- 1999-03-24 DE DE69929041T patent/DE69929041T2/de not_active Expired - Fee Related
- 1999-03-24 CZ CZ20003419A patent/CZ297284B6/cs not_active IP Right Cessation
- 1999-03-24 ES ES99914882T patent/ES2255255T3/es not_active Expired - Lifetime
- 1999-03-24 AT AT99914882T patent/ATE313326T1/de not_active IP Right Cessation
- 1999-03-24 CA CA002320204A patent/CA2320204A1/en not_active Abandoned
- 1999-03-24 SK SK1331-2000A patent/SK13312000A3/sk unknown
- 1999-03-24 DK DK99914882T patent/DK1066038T3/da active
- 1999-03-24 KR KR1020007010666A patent/KR100597517B1/ko not_active Expired - Fee Related
- 1999-03-24 NZ NZ507176A patent/NZ507176A/en unknown
- 1999-03-24 BR BR9908953-0A patent/BR9908953A/pt not_active Application Discontinuation
- 1999-03-24 EP EP99914882A patent/EP1066038B1/de not_active Expired - Lifetime
- 1999-03-24 JP JP2000537534A patent/JP2002507562A/ja active Pending
- 1999-03-24 IL IL13852299A patent/IL138522A0/xx unknown
- 1999-03-24 EA EA200000994A patent/EA002554B1/ru not_active IP Right Cessation
2000
- 2000-08-28 ZA ZA200004452A patent/ZA200004452B/xx unknown
- 2000-09-26 NO NO20004799A patent/NO20004799L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO20004799L (no)	2000-10-11
IL138522A0 (en)	2001-10-31
NZ507176A (en)	2003-09-26
HUP0101954A2 (hu)	2001-12-28
BR9908953A (pt)	2000-12-05
DK1066038T3 (da)	2006-04-24
ATE313326T1 (de)	2006-01-15
JP2002507562A (ja)	2002-03-12
ZA200004452B (en)	2002-02-27
AU3353199A (en)	1999-10-18
EA002554B1 (ru)	2002-06-27
HUP0101954A3 (en)	2002-09-30
US6114326A (en)	2000-09-05
WO1999048484A2 (en)	1999-09-30
SK13312000A3 (sk)	2001-05-10
TR200002759T2 (tr)	2001-02-21
PL343593A1 (en)	2001-08-27
DE69929041D1 (de)	2006-01-26
KR100597517B1 (ko)	2006-07-10
DE69929041T2 (de)	2006-07-20
CN1303286A (zh)	2001-07-11
EP1066038B1 (de)	2005-12-21
EA200000994A1 (ru)	2001-02-26
CA2320204A1 (en)	1999-09-30
AU747751B2 (en)	2002-05-23
CZ20003419A3 (cs)	2002-01-16
WO1999048484A3 (en)	1999-11-25
EP1066038A2 (de)	2001-01-10
KR20010052222A (ko)	2001-06-25
CZ297284B6 (cs)	2006-10-11
NO20004799D0 (no)	2000-09-26

Publication	Publication Date	Title
EP1066038B1 (de)	2005-12-21	Verwendung von cabergolin zur behandlung von "restless legs syndrom"
Freye et al.	2000	Acute abstinence syndrome following abrupt cessation of long‐term use of tramadol (Ultram®): a case study
JP2009073842A (ja)	2009-04-09	苦痛を管理しおよび薬物依存性を軽減するための、ケタミンの投与
US8703823B2 (en)	2014-04-22	Methods for treatment of migraine and symptoms thereof
WO2006055854A2 (en)	2006-05-26	Methods for reducing the side effects associated with mirtazapine treatment
Halpern	1977	Analgesic drugs in the management of pain
EP1154795B1 (de)	2005-08-17	Vorrichtungen zur behandlung und diagnose des restless leg syndroms
JPS59193821A (ja)	1984-11-02	抗不安薬としてのフルオキセチンの使用法
US6855735B2 (en)	2005-02-15	Ketamine treatment of restless legs syndrome
ES2967484T3 (es)	2024-04-30	Tratamiento de los síntomas inducidos por el ciclo menstrual
US11744833B2 (en)	2023-09-05	Pharmaceutical compositions and methods for treatment of insomnia
JP2000502318A (ja)	2000-02-29	Ｎ−Ｌ−α−アスパルチル−Ｌ−フェニルアラニン１−メチルエステルの鎮痛剤としての使用
WO2008120966A1 (es)	2008-10-09	Composición farmacéutica en forma de tableta sublingual que comprende un antiinflamatorio no esteroideo y un analgésico opiáceo para el manejo del dolor.
Folks et al.	1998	Sedative hypnotics and sleep
WO2023158424A1 (en)	2023-08-24	Novel pharmaceutical compositions and methods for treatment of insomnia
Williams	1997	Tramadol hydrochloride: something new in oral analgesic therapy
Driscoll	1987	Pain management
EP1477168A1 (de)	2004-11-17	Verwendung von Cabergolin zur Behandlung von "restless legs syndrom"
MXPA00009395A (en)	2001-07-09	Use of cabergoline in the treatment of restless legs syndrome
Somi et al.	2019	Anaesthetic implications of restless legs syndrome: A review
Trapp	1989	An evaluation of Droperidol for preventing nausea and vomiting after deep intravenous sedation for ambulatory dental surgery
HK1037324A (en)	2002-02-08	Use of cabergoline in the treatment of restless legs syndrome
Montagna et al.	2008	Treatment of Sleep-Related Movement Disorders
CA2524090A1 (en)	2004-12-09	Use of tripolidine in providing refreshedness on waking
Parkes et al.	1987	Disorders of Sleep and Wakefulness